Business Context and Reporting Period
Company: MEDICINOVA INC
Filing Type: Form 8-K (Current Report)
Date of Report: September 12, 2007
Event: Execution of Severance Protection Agreements with key officers.
Key Financial Metrics
This filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation arrangements.
Material Changes
On September 12, 2007, the Company entered into Severance Protection Agreements with five officers: Yuichi Iwaki, M.D., Ph.D., Shintaro Asako, Richard E. Gammans, Ph.D., Kenneth W. Locke, Ph.D., and Masatsune Okajima.
Guidance, Outlook, and Management Commentary
Severance Terms:
- Trigger Events: Involuntary termination without cause or resignation for good reason within 12 months following a change of control.
- Compensation: Accrued salary, pro rata bonus, and a lump sum equal to two times the officer's base salary and bonus amount.
- Benefits: 24 months of life insurance, disability, medical, dental, and hospitalization benefits; up to 12 months of outplacement counseling.
- Equity: Accelerated vesting under existing equity incentive plans.
- Tax Provision: Payments will be reduced if necessary to avoid excise taxes under the Internal Revenue Code.
- Initial expiration: December 31, 2007.
- Automatic renewal for one-year periods unless written notice of non-renewal is provided by October 1 of the applicable year.
- Financial liability is contingent upon a change of control and subsequent qualifying termination.
- Liability is subject to reduction to avoid excise taxes.
Investor Verification Checklist
- Verify the specific base salary and bonus amounts for the five named officers to calculate potential severance liabilities.
- Review the full text of the Severance Protection Agreement filed as Exhibit 10.1 for detailed definitions of "good reason" and "change of control."
- Assess the Company's current cash position to determine the ability to fund potential lump-sum payments if a change of control occurs.
- Confirm the status of the Company's equity incentive plans to understand the impact of accelerated vesting.